(Q33375448)

26 July 2017

1 reference

title

Fondaparinux as a treatment option for heparin-induced thrombocytopenia (English)

1 reference

heparin-induced thrombocytopenia

26 July 2017

1 reference

1 reference

Stella Papadopoulos

1

1 reference

26 July 2017

Jeremy D Flynn

series ordinal

2

1 reference

26 July 2017

Daniel A Lewis

series ordinal

3

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

26 July 2017

1 reference

26 July 2017

volume

27

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

921-926

1 reference

Treatment of heparin-induced thrombocytopenia

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

Clinical practice. Heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

Heparin-induced thrombocytopenia: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

Unfractionated heparin: focus on a high-alert drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

Treatment of heparin-induced thrombocytopenia: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

Heparin overview and issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.921

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.6.921

1 reference

26 July 2017

1 reference